文献速递中医内科中药与中成药合理使用

养心定悸胶囊辅助治疗房颤的系统评价与Meta分析

Efficacy and safety of Yangxin Dingji capsule as an adjunctive therapy for atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · Front Pharmacol · 2026-10-14

该系统评价纳入10项RCT共872例房颤患者,评估养心定悸胶囊联合常规治疗对比单用常规治疗的疗效与安全性。结果显示其在临床症状、心脏功能及炎症标志物方面可能有额外获益,但多数结局证据质量低或极低,仅LVEF和术后6个月房颤复发为中等质量,结论需谨慎解释。

要点

  • 养心定悸胶囊辅助治疗可能改善房颤患者临床症状和心脏功能。
  • 多数疗效结局证据质量低或极低,结论仅为探索性。
  • 不应替代指南导向的抗凝、率律控制或导管消融治疗。

核心结论

  • 现有证据仅提供初步信号:养心定悸胶囊作为常规治疗辅助,可能对房颤症状控制和术后管理有额外获益。
  • 多数疗效结局为低或极低质量证据,仅LVEF和术后6个月房颤复发为中等质量。
  • 结论应视为探索性和假设生成性,需严格设计试验验证。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Embase、Web of Science、Cochrane Library、CBM、万方、维普及CNKI至2026年4月1日。
  • 纳入10项RCT,共872例房颤患者,比较养心定悸胶囊联合常规治疗与单用常规治疗。
  • 使用RevMan进行Meta分析,RoB 2评估偏倚风险,GRADE框架评价证据质量,PROSPERO注册号CRD420261286691。

主要发现

  • 临床症状:总临床有效率RR=1.27(P<0.00001,极低质量),EHRA症状评分MD=-0.47(P=0.0009,极低质量),术后6个月房颤复发RR=0.43(P=0.03,中等质量)。
  • 心脏功能:LAEF MD=2.11%(P=0.003,低质量),LVEF MD=4.39%(P<0.00001,中等质量);LAD MD=-1.97 mm(P=0.07,极低质量),二尖瓣E/A比值MD=0.12(P=0.06,极低质量);亚组分析术后患者LAD MD=-2.70 mm(P=0.02,低质量)。
  • 炎症标志物:hs-CRP MD=-1.21 mg/L(P<0.00001,低质量),TNF-α SMD=-0.44(P=0.0009,低质量),IL-6 MD=-10.42 ng/L(P<0.00001,低质量);亚组分析术后患者hs-CRP MD=-1.42 mg/L(P<0.00001,低质量)。
  • 安全性:不良事件总体发生率未见明显增加,RR=0.58(P=0.07,低质量)。
  • 单项研究探索性分析提示可能长期获益,包括缺血性卒中风险降低及消融术后9个月房颤复发和症状评分持续降低,但需进一步确认。

临床怎么用

  • 养心定悸胶囊可作为常规治疗的辅助,用于房颤症状控制和术后管理,但证据质量有限。
  • 不应替代指南导向的抗凝、率律控制或导管消融治疗。
  • 临床决策需结合患者具体情况,并告知证据的探索性性质。

局限性

  • 所有纳入研究均为中文发表、单中心、小样本,方法学存在局限。
  • 多数研究RoB 2评估为存在一定担忧或高偏倚风险,主要因分配隐藏不充分、主观结局缺乏盲法及无公开注册方案。
  • 大多数疗效结局证据质量低或极低,仅LVEF和术后6个月房颤复发为中等质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Yangxin Dingji Capsule (YXDJ), a modern Chinese patent medicine derived from the classic Zhigancao Decoction, is commonly used as an adjuvant therapy for atrial fibrillation (AF). This study aimed to comprehensively evaluate the efficacy and safety of YXDJ as an adjuvant therapy in AF patients. MATERIALS AND METHODS: We systematically searched PubMed, Embase, Web of Science, Cochrane Library, China Biology Medicine, Wanfang, VIP Chinese Journal Service Platform, and China National Knowledge Infrastructure from inception to 1 April 2026, for randomized controlled trials (RCTs) comparing YXDJ plus conventional therapy versus conventional therapy alone in patients with AF. Meta-analyses were performed using RevMan with fixed- or random-effects models based on heterogeneity. Risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB 2) tool, and the overall quality of evidence for each outcome was evaluated using the GRADE framework. The protocol was registered in PROSPERO (CRD420261286691). RESULTS: Ten RCTs involving 872 patients were included. All studies were Chinese-language publications with methodological limitations. According to the RoB 2 assessment, most studies were rated as having some concerns or high risk of bias, mainly due to inadequate allocation concealment, lack of blinding for subjective outcomes, and absence of publicly available trial registrations or protocols. In terms of clinical symptoms, YXDJ was associated with improvements in the overall clinical response rate [RR = 1.27, P < 0.00001, very low], reductions in EHRA symptom scores [MD = -0.47, P = 0.0009, very low], and reductions in postoperative AF recurrence at 6 months [RR = 0.43, P = 0.03, moderate]. For cardiac function, YXDJ was associated with increases in left atrial ejection fraction (LAEF) [MD = 2.11%, P = 0.003, low] and left ventricular ejection fraction (LVEF) [MD = 4.39%, P < 0.00001, moderate], whereas no significant changes were observed in left atrial diameter (LAD) [MD = -1.97 mm, P = 0.07, very low] and mitral E/A ratio [MD = 0.12, P = 0.06, very low]; subgroup analysis revealed that YXDJ reduced LAD in postoperative patients [MD = -2.70 mm, P = 0.02, low]. In terms of inflammatory biomarkers, YXDJ was associated with reductions in hs-CRP [MD = -1.21 mg/L, P < 0.00001, low], TNF-α [SMD = -0.44, P = 0.0009, low], and IL-6 [MD = -10.42 ng/L, P < 0.00001, low]; subgroup analysis further showed a greater reduction in hs-CRP in postoperative patients [MD = -1.42 mg/L, P < 0.00001, low]. For safety, no clear increase in the overall incidence of adverse events was observed [RR = 0.58, P = 0.07, low]. Exploratory analyses from single studies suggested possible long-term benefits, including a lower reported risk of ischemic stroke and sustained reductions in AF recurrence and symptom scores at 9 months post-ablation; however, these findings are preliminary and require confirmation. CONCLUSION: Current evidence, derived exclusively from methodologically limited, small, single-center Chinese studies, provides only preliminary signals that YXDJ may offer possible additional benefits as an adjunct to conventional therapy for symptom control and postoperative management in AF. Most efficacy outcomes were supported by low- or very-low-certainty evidence, with only LVEF and postoperative AF recurrence at 6 months rated as moderate certainty. These findings should be regarded as exploratory and hypothesis-generating. YXDJ should not replace guideline-directed anticoagulation, rate or rhythm control, or catheter ablation. Rigorously designed trials are needed to confirm its efficacy and safety. SYSTEMATIC REVIEW: Identifier CRD420261286691.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Hao, Ma, Ren, et al. Efficacy and safety of Yangxin Dingji capsule as an adjunctive therapy for atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2026. PMID: 42952871. doi:10.3389/fphar.2026.1952214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。